 - Patients who received prior taxane-based chemotherapy as neoadjuvant or adjuvant therapy for local disease, or who received taxane-based therapy in the PSA clinical non-metastatic state is allowable provided that the total duration of exposure was six cycles or less and chemotherapy was completed more than 6 months prior to registration 